- Home
- NEGG vs MOLN Comparison
NEGG vs MOLN Comparison
Compare NEGG & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEGG | MOLN |
|---|---|---|
| Founded | 2001 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 164.2M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NEGG | MOLN |
|---|---|---|
| Price | $52.01 | $4.22 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.75 |
| AVG Volume (30 Days) | ★ 115.4K | 3.9K |
| Earning Date | 04-24-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,313,127,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $999.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.32 | $3.36 |
| 52 Week High | $137.84 | $5.91 |
Technical Indicators
Market Signals| Indicator | NEGG | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 38.23 | 48.42 |
| Support Level | $50.00 | $4.16 |
| Resistance Level | $53.57 | $4.44 |
| Average True Range (ATR) | 4.14 | 0.18 |
| MACD | -0.53 | -0.02 |
| Stochastic Oscillator | 15.83 | 44.12 |
Price Performance
Historical ComparisonAbout NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.